Denali Therapeutics Inc. – Filings and Transcripts

NASDAQ: DNLI
Share price (7/2/26): $25.83
Market cap (7/2/26): $4.099 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Automatic shelf registration

Ownership Filter

Van Hauwermeiren Timothy

Thornberry Nancy

Cook Jennifer E.

Krognes Steve E.

Schenkein David P

News Filter

Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Shareholder Vote Results, Financial Statements or Exhibits

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

Reports First Quarter 2026 Financial Results and Business Highlights

Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Letter from the SEC